259 related articles for article (PubMed ID: 34793338)
21. HDAC11 inhibition disrupts porcine oocyte meiosis via regulating α-tubulin acetylation and histone modifications.
Huang R; Sui L; Fu C; Zhai Y; Dai X; Zhang S; Li Z
Aging (Albany NY); 2021 Mar; 13(6):8849-8864. PubMed ID: 33742608
[TBL] [Abstract][Full Text] [Related]
22. [Role of HDAC isoforms and development of treatment of multiple myeloma using isoform-specific HDAC inhibitors].
Harada T
Rinsho Ketsueki; 2019; 60(9):1265-1274. PubMed ID: 31597852
[TBL] [Abstract][Full Text] [Related]
23. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y
Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303
[TBL] [Abstract][Full Text] [Related]
24. Trapoxin A Analogue as a Selective Nanomolar Inhibitor of HDAC11.
Ho TT; Peng C; Seto E; Lin H
ACS Chem Biol; 2023 Apr; 18(4):803-809. PubMed ID: 36977486
[TBL] [Abstract][Full Text] [Related]
25. New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
Cea M; Cagnetta A; Gobbi M; Patrone F; Richardson PG; Hideshima T; Anderson KC
Curr Pharm Des; 2013; 19(4):734-44. PubMed ID: 23016853
[TBL] [Abstract][Full Text] [Related]
26. HDAC11: a multifaceted histone deacetylase with proficient fatty deacylase activity and its roles in physiological processes.
Núñez-Álvarez Y; Suelves M
FEBS J; 2022 May; 289(10):2771-2792. PubMed ID: 33891374
[TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.
Minami J; Suzuki R; Mazitschek R; Gorgun G; Ghosh B; Cirstea D; Hu Y; Mimura N; Ohguchi H; Cottini F; Jakubikova J; Munshi NC; Haggarty SJ; Richardson PG; Hideshima T; Anderson KC
Leukemia; 2014 Mar; 28(3):680-9. PubMed ID: 23913134
[TBL] [Abstract][Full Text] [Related]
28. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z
Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790
[TBL] [Abstract][Full Text] [Related]
29. Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors.
Tian Y; Lv W; Li X; Wang C; Wang D; Wang PG; Jin J; Shen J
Bioorg Med Chem Lett; 2017 Jul; 27(13):2943-2945. PubMed ID: 28501514
[TBL] [Abstract][Full Text] [Related]
30. Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies.
Imai Y; Maru Y; Tanaka J
Cancer Sci; 2016 Nov; 107(11):1543-1549. PubMed ID: 27554046
[TBL] [Abstract][Full Text] [Related]
31. HDAC11 promotes meiotic apparatus assembly during mouse oocyte maturation via decreasing H4K16 and α-tubulin acetylation.
Sui L; Zhang S; Huang R; Li Z
Cell Cycle; 2020 Feb; 19(3):354-362. PubMed ID: 31910069
[TBL] [Abstract][Full Text] [Related]
32. Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma.
Berdeja JG; Laubach JP; Richter J; Stricker S; Spencer A; Richardson PG; Chari A
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):752-765. PubMed ID: 34340951
[TBL] [Abstract][Full Text] [Related]
33. Garcinol Is an HDAC11 Inhibitor.
Son SI; Su D; Ho TT; Lin H
ACS Chem Biol; 2020 Nov; 15(11):2866-2871. PubMed ID: 33034447
[TBL] [Abstract][Full Text] [Related]
34. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.
Richardson PG; Laubach JP; Lonial S; Moreau P; Yoon SS; Hungria VT; Dimopoulos MA; Beksac M; Alsina M; San-Miguel JF
Expert Rev Anticancer Ther; 2015; 15(7):737-48. PubMed ID: 26051506
[TBL] [Abstract][Full Text] [Related]
35. Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.
Imai Y; Ohta E; Takeda S; Sunamura S; Ishibashi M; Tamura H; Wang YH; Deguchi A; Tanaka J; Maru Y; Motoji T
JCI Insight; 2016 Apr; 1(5):e85061. PubMed ID: 27699258
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitor BG45-mediated HO-1 expression induces apoptosis of multiple myeloma cells by the JAK2/STAT3 pathway.
Tang S; Cheng B; Zhe N; Ma D; Xu J; Li X; Guo Y; Wu W; Wang J
Anticancer Drugs; 2018 Jan; 29(1):61-74. PubMed ID: 29049036
[TBL] [Abstract][Full Text] [Related]
37. Gender-specific role of HDAC11 in kidney ischemia- and reperfusion-induced PAI-1 expression and injury.
Kim JI; Jung KJ; Jang HS; Park KM
Am J Physiol Renal Physiol; 2013 Jul; 305(1):F61-70. PubMed ID: 23657855
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.
Ramakrishnan VG; Miller KC; Macon EP; Kimlinger TK; Haug J; Kumar S; Gonsalves WI; Rajkumar SV; Kumar SK
Haematologica; 2019 Oct; 104(10):2061-2074. PubMed ID: 30846494
[TBL] [Abstract][Full Text] [Related]
39. Panobinostat for the treatment of multiple myeloma.
Neri P; Bahlis NJ; Lonial S
Expert Opin Investig Drugs; 2012 May; 21(5):733-47. PubMed ID: 22404247
[TBL] [Abstract][Full Text] [Related]
40. Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups.
Li Y; Wang F; Chen X; Wang J; Zhao Y; Li Y; He B
Curr Top Med Chem; 2019; 19(3):223-241. PubMed ID: 30674261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
